Association Between Plasma Brain Natriuretic Peptide and Overall Survival in Patients With Advanced Cancer: Preliminary Findings

Plain-language guide to PMID 31128228 (2019): multicenter randomized controlled trial study of BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide).

Key Facts

PMID: 31128228
Journal: Journal of pain and symptom management
Year: 2019
Study type: Randomized Controlled Trial
Authors: Hui D et al. (6 authors)
DOI: 10.1016/j.jpainsymman.2019.05.006

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

Their objective was to examine the association between plasma natriuretic peptides and survival in patients with advanced cancer without clinical evidence of heart failure.

Why It Was Studied

Atrial and brain natriuretic peptides (ANP and BNP) are established diagnostic and prognostic markers in heart failure, but their utility in patients with advanced cancer is unclear.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

This exploratory analysis of a multicenter, randomized clinical trial of cancer patients receiving hospice care assessed the association between elevated plasma ANP, BNP, or Pro-BNP (cutoffs of >77, 100, and 900 pg/mL, respectively) and overall survival.

How the Study Was Run

The design is described as randomized and multicenter.

The participants were allocated by chance, so the BNP (Nesiritide) group and the comparison group should start out alike.

Running at several centres spread the BNP (Nesiritide) study over different clinics and patient groups.

Time-to-event analyses, including multivariate Cox regression, were conducted.

What Was Measured

Topics PubMed links to this paper include Atrial Natriuretic Factor, Natriuretic Peptide, Brain, Neoplasms, Prognosis and Survival Rate.

Author keywords: palliative care.

What This Means in Plain Language

The paper is a randomized and multicenter study of BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Journal of pain and symptom management), a journal based in United States.

More context: the BNP (Nesiritide) compound page and the ANP (Atrial Natriuretic Peptide) compound page, all human trials.

Our Notes on the Compounds

BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.

ANP (Atrial Natriuretic Peptide): A 28-amino-acid heart hormone that relaxes blood vessels and increases salt excretion; carperitide is a recombinant form.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.